Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia
- 1 August 2016
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 82, 425-431
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Synergistic Effects of Celecoxib and Bupropion in a Model of Chronic Inflammation-Related Depression in MicePLOS ONE, 2013
- Serum and gene expression profile of cytokines in first-episode psychosisBrain, Behavior, and Immunity, 2013
- Does Long-Term Treatment of Schizophrenia With Antipsychotic Medications Facilitate Recovery?Schizophrenia Bulletin, 2013
- Cost of disorders of the brain in Europe 2010European Neuropsychopharmacology, 2011
- Increased annexin-V and decreased TNF-alpha serum levels in chronic-medicated patients with schizophreniaNeuroscience Letters, 2011
- Abuse of Amphetamines and Structural Abnormalities in the BrainAnnals of the New York Academy of Sciences, 2008
- Persistent downregulation of hippocampal CREB mRNA parallels a Y‐maze deficit in adolescent rats following semi‐chronic amphetamine administrationBritish Journal of Pharmacology, 2008
- Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1 -null miceProceedings of the National Academy of Sciences, 2008
- Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortexSchizophrenia Research, 2008
- Molecular genetics of schizophrenia: a review of the recent literatureCurrent Opinion in Psychiatry, 2003